SynOx Therapeutics Limited

SynOx Therapeutics is a late-stage clinical biopharmaceutical company developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other macrophage-driven disorders. The company focuses on providing effective therapies for rare and debilitating diseases with a focus on improving patient quality of life. Emactuzumab has shown significant clinical activity in earlier trials.

+ 0 Upvotes
Buy Funded Startups lists